^（153）Sm－EDTMP治疗多发性骨转移癌的临床研究

^(153)Sm-EDTMP FOR TREATMENT OF MULTIPLE OSSEOUS METASTASES

用^（１５３）Ｓｍ－乙二胺四亚甲基磷酸（ＥＤＴＭＰ）治疗４１例多发性骨转移癌，其原发癌均有病理检查证实，按１４．８～２９．６ＭＢｑ／ｋｇ计算，每次剂量范围７４０～２１０９ＭＢｑ．一般病人接受１～３次治疗，１例接受５次．两次治疗间隔３～５周．止痛有效率为９２．７％（３８／４１），治疗后部分病人骨转移灶缩小变淡和消退．文中讨论了剂量、不良反应和影响疗效的因素等，认为用^（１５３）Ｓｍ－ＥＤＴＭＰ治疗多发性骨转移癌疗效好，副反应小，使用安全，值得临床推广应用．

Abstract patients with multiple osseous metastases of cancer were treated with￣(153)Sm-EDTMP.All primary cancer were pathologically proved,including 17 breast cancer,16 lung cancer,2 prostate cancer, 2nasopharyngeal cancer and 4 others.The radioactive doses of￣(153)Sm-EDTMP ranged from 14.8￣29.6MBq/kg,i.e.,a total activity was given to each patient ranged from 740￣2109 MBq.The response to therapy was as follows:43.9%(18/41)achieved complete relief pain,48.8%(20/41)achieved partial relief pain and no response was found in 7.2%(3/41).The systemic radioactive effects on patients were mild,leukocytes and plateletes were only temporally decreased.￣(153)Sm-EDTMP is a promising radiopharmaceutical because of a good response,less adverse effects and safety.